Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
Jamunarani Veeraraghavan(Baylor College of Medicine), Rachel Schiff(Baylor College of Medicine), Irmina Diala(Puma Biotechnology (United States)), Carolina Gutiérrez(Baylor College of Medicine), Carmine De Angelis(Baylor College of Medicine), C. Kent Osborne(Baylor College of Medicine), Vidyalakshmi Sethunath(Dana-Farber Cancer Institute), Chandandeep Nagi(Icahn School of Medicine at Mount Sinai), Robert Davis(Baylor College of Medicine), Mario Giuliano(Regione Campania), Sepideh Mehravaran(Baylor College of Medicine), Sarmistha Nanda(Baylor College of Medicine), Mothaffar F. Rimawi(Baylor College of Medicine), Susan G. Hilsenbeck(Baylor College of Medicine), Kristina Goutsouliak(Baylor College of Medicine), Resel Pereira(Baylor College of Medicine), Tao Wang(Pfizer (United States)), Lanfang Qin(Pancreatic Cancer Action Network), Martin J. Shea(Baylor College of Medicine), Tamika Mitchell(Baylor College of Medicine), Alshad S. Lalani(Puma Biotechnology (United States))
Cited by 11
Related Papers
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
|Proceedings of the National Academy of Sciences|2013|833
Targeting cardiac fibrosis with engineered T cells
|Nature|2019|799